KUPPUSAMY KARTHIK sold $1.6M of DGX
KUPPUSAMY KARTHIK (SVP, Clinical Solutions) sold 8,147 shares of QUEST DIAGNOSTICS INC (DGX) at $200.00 ($1.63M total) on 2026-06-04 under a Rule 10b5-1 trading plan.
How this was made
The 30-second read
Why it matters
The newest concrete fact is the specific open-market sale size, price, and 10b5-1 status by a clinical solutions SVP; this can marginally influence sentiment but rarely drives fundamentals.
Market read
A $1.63M insider sale under 10b5-1 is a modest sentiment datapoint for DGX, with limited standalone trading impact.
What to watch
Traders should check whether DGX has concurrent fundamental catalysts (earnings, guidance, contract/regulatory updates) since Form 4 alone is usually low-signal.
Background
The article is an SEC Form 4 insider transaction disclosure for Quest Diagnostics (DGX).
Ticker impact
Quest Diagnostics SVP Kuppusamy Karthik sold 8,147 shares (~$1.63M) in an open-market transaction under a 10b5-1 plan.
Low likelihood of a sustained price move; any reaction is likely short-lived unless accompanied by other news.
The filing is a disclosed sale (not a buy), but it is explicitly under a pre-arranged 10b5-1 plan, which typically reduces signal strength.
Market effects
Minimal; single-insider Form 4 selling does not reset sector fundamentals.
None indicated.
None indicated.
Counterpoint
Because the sale is on a 10b5-1 plan, it may reflect liquidity/tax planning rather than bearish expectations.
Key entities
- issuerQuest Diagnostics Inc.
DGX, the company whose insider transaction was disclosed.
- insiderKuppusamy Karthik
SVP, Clinical Solutions; sold 8,147 shares under a pre-arranged 10b5-1 plan.
